Literature DB >> 2111183

Neuroendocrine aspects of primary endogenous depression. X: Serum growth hormone measures in patients and matched control subjects.

R T Rubin1, R E Poland, I M Lesser.   

Abstract

To determine the extent of dysregulation of growth hormone (GH) secretion in endogenous depression, we measured nocturnal serum GH concentrations and GH responses to thyrotropin-releasing hormone (TRH, gonadotropin-releasing hormone (LHRH), and dexamethasone administration in 40 Research Diagnostic Criteria primary, definite endogenous depressives and 40 individually matched normal control subjects. Compared with their controls, the patients showed no difference in basal nocturnal GH concentrations or in GH responses to TRH or LHRH. The GH measures were not significantly related to the other endocrine measures reported previously, including dexamethasone suppression test status. None of the diagnostic schemes for endogenous/melancholic depression which we studied was significantly related to the GH measures in the patients. Of the other subject and symptom variables, the mood depression factor of the Hamilton depression scale and the performance difficulty factor of the Beck depression inventory were moderately negatively correlated with the nocturnal GH measures. These findings suggest that, in contrast to the previously reported hypothalamopituitary-adrenal cortical and thyroid axis abnormalities in our patients, GH secretion was relatively normal. Patients with more severe depressed mood and greater difficulty accomplishing tasks did have moderately lower nocturnal GH values.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2111183     DOI: 10.1016/0006-3223(90)90044-3

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  3 in total

Review 1.  Endocrine disturbances in depression.

Authors:  M A Tichomirowa; M E Keck; H J Schneider; M Paez-Pereda; U Renner; F Holsboer; G K Stalla
Journal:  J Endocrinol Invest       Date:  2005-01       Impact factor: 4.256

2.  The influence of 4-week treatment with sertraline on the combined T3/TRH test in depressed patients.

Authors:  Cornelius Schüle; Thomas C Baghai; Lejla Alajbegovic; Markus Schwarz; Peter Zwanzger; Daniela Eser; Ludwig Schaaf; Hans-Jürgen Möller; Rainer Rupprecht
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-03-05       Impact factor: 5.270

3.  Serial mitogen-stimulated cytokine production from continuously ill patients with schizophrenia.

Authors:  Mark H Rapaport; Catherine Bresee
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.